Modified Viral Particles with Immunogenic Properties and Reduced Lipid Content Useful for Treating and Preventing Infectious Diseases

• US 20090028902A1
• Filed: 05/09/2008
• Published: 01/29/2009
• Est. Priority Date: 06/29/2000
• Status: Abandoned Application

• Current Assignee: Eli Lilly and Company
• Original Assignee: Lipid Sciences, Inc.
• Inventors: Maltais, Jo-Ann B., Cham, Bill E., Bellotti, Marc
• Application Number:
  US12/118,451
• Publication Number:
  US 20090028902A1
• Time in Patent Office: Days
• US Class Current: 424/204.100
• CPC Class Codes: A61K 2039/5252 inactivated (killed)
• CPC Class Codes: A61K 2039/55566 Emulsions, e.g. Freund's adjuvant, MF59
• CPC Class Codes: A61K 2039/57 characterised by the type of response, e.g. Th1, Th2
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 39/29 Hepatitis virus
• CPC Class Codes: A61K 39/292 Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
• CPC Class Codes: A61L 2/0011 using physical methods
• CPC Class Codes: A61L 2/0088 Liquid substances
• CPC Class Codes: A61M 1/3486 Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: C12N 2730/10134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2730/10163 by chemical treatment
• CPC Class Codes: C12N 2740/15034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2740/15063 by chemical treatment
• CPC Class Codes: C12N 2770/20034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2770/24063 by chemical treatment
• CPC Class Codes: C12N 2770/24334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2770/24363 by chemical treatment
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

The present invention relates to a method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious viral organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious viral organism thereby creating modified viral particles with reduced infectivity and enhanced antigenicity. The present invention provides vaccine compositions, comprising these modified viral particles with reduced infectivity and enhanced antigenicity, optionally combined with a pharmaceutically acceptable carrier or an immunostimulant. The vaccine composition is administered to a patient to provide protection against the lipid-containing infectious viral organism. The vaccine compositions of the present invention include combination vaccines of modified viral particles obtained from one or more strains of a virus and/or one or more types of virus.

Claims

1. A modified pestivirus viral particle comprising at least a partially delipidated pestivirus viral particle, wherein the partially delipidated pestivirus viral particle:

initiates a positive immune response in a patient; and

incites protection against an infectious organism.

3. The modified pestivirus viral particle of claim 1, wherein the modified pestivirus viral particle has a lower cholesterol content than an unmodified viral particle.

4. The modified pestivirus viral particle of claim 3, wherein the lower cholesterol content is at least 20% lower than the unmodified pestivirus viral particle.

5. The modified pestivirus viral particle of claim 3, wherein the lower cholesterol content is at least 30% lower than the unmodified pestivirus viral particle.

6. The modified pestivirus viral particle of claim 3, wherein the lower cholesterol content is at least 40% lower than the unmodified pestivirus viral particle.

7. The modified pestivirus viral particle of claim 1, wherein the modified pestivirus viral particle has a different buoyant density than an unmodified viral particle.

2. (canceled)

8-13. -13. (canceled)

14. A modified pestivirus viral particle comprising at least a partially delipidated pestivirus viral particle having:

a lower cholesterol content than an unmodified pestivirus viral particle; and

,

a different buoyant density than an unmodified pestivirus viral particle.

18. The modified pestivirus viral particle of claim 14, wherein the lower cholesterol content is at least 20% lower than the unmodified pestivirus viral particle.

19. The modified pestivirus viral particle of claim 14, wherein the lower cholesterol content is at least 30% lower than the unmodified pestivirus viral particle.

20. The modified pestivirus viral particle of claim 14, wherein the lower cholesterol content is at least 40% lower than the unmodified pestivirus viral particle.

15-17. -17. (canceled)

21-28. -28. (canceled)

29. A vaccine composition, comprising at least a partially delipidated pestivirus viral particle having at least one exposed viral antigen that was not exposed in the non-delipidated pestivirus viral particle wherein the partially delipidated pestivirus viral particle is capable of provoking an immune response when administered to a patient.

30. The vaccine composition of claim 29, wherein the immune response comprises enhanced interferon gamma production by T cells.

31. The vaccine composition of claim 30, wherein the T cells are CD4⁺ or CD8⁺ T cells.

32. The vaccine composition of claim 29, wherein the immune response comprises proliferation of cells of the immune system.

33. The vaccine composition of claim 29, wherein the partially delipidated pestivirus viral particle has a lower cholesterol content than the non-delipidated pestivirus viral particle.

34. The vaccine composition of claim 33, wherein the lower cholesterol content is at least 20% lower than the non-delipidated pestivirus viral particle.

35. The vaccine composition of claim 33, wherein the lower cholesterol content is at least 30% lower than the non-delipidated pestivirus viral particle.

36. The vaccine composition of claim 29, comprising partially delipidated pestivirus viral particles from one or more strains of virus or one or more types of virus.

37. The vaccine composition of claim 29, wherein the partially delipidated pestivirus viral particle has a different buoyant density than the non-delipidated pestivirus viral particle.

43. The vaccine composition of claim 29, wherein the pestivirus is BVDV.

38-42. -42. (canceled)

44-69. -69. (canceled)